Patient Safety and Risk Management

PS-021

NATALIZUMAB DISCONTINUATION IN PATIENTS DIAGNOSED WITH RELAPSING REMITTING MULTIPLE SCLEROSIS

PS-017

CORRECTIVE ACTIONS AFTER PARTICIPATING IN THE STUDY MULTICENTRE WATCHING FOR DETECTION OF MEDICATION ERRORS (EMOPEM)

PS-016

MEDICATION SAFETY IN NEONATAL CARE: ANALYSIS OF HIGH-ALERT MEDICATIONS

PS-015

 THE DEVELOPMENT OF A VIDEO TO DEMONSTRATE EXTEMPORANEOUS EYE DROP PREPARATION FOR USE BY COMMUNITY PHARMACISTS 

PS-014

AN OBSERVATIONAL REVIEW AND AUDIT OF THE TREATMENT OF HYPOGLYCAEMIC EVENTS IN A UNIVERSITY TEACHING HOSPITAL 

PS-013

MULTICENTER STUDY OF ENVIRONMENTAL CONTAMINATION WITH CYCLOPHOSPHAMIDE, IFOSFAMIDE AND METHOTREXATE IN 66 CANADIAN HOSPITALS: 2016 FOLLOW-UP STUDY 

PS-012

SURFACE CONTAMINATION IN A TEACHING HOSPITAL: A 6-YEAR PERSPECTIVE

PS-010

EVALUATION OF A CLINICAL DECISION SUPPORT SYSTEM (CDSS) TO OPTIMIZE CYTOTOXIC DRUG DOSING AND CONTINUOUS SURVEILLANCE IN OUTPATIENT CANCER PATIENTS WITH RENAL IMPAIRMENT

PS-006

ANALYSIS OF DRUG RELATED PROBLEMS AND PHARMACIST’S RECOMENDATION OF HOSPITALISED PATIENTS WITH CHRONIC KIDNEY DISEASE AT A MAJOR TEACHING HOSPITAL IN JAKARTA

PS-036

IMPROVING PHARMACOLOGICAL TREATMENT: REAL-TIME SAFETY AUDITS

PS-049

PROSPECTIVE DETECTION OF ADVERSE DRUG REACTIONS AMONG 2,263 HOSPITALISED CHILDREN OVER A 19 MONTH PERIOD

PS-046

Materiovigilance ex ante risk management

PS-037

PHARMACEUTICAL INTERVENTIONS IN A TEACHING HOSPITAL

PS-080

DRUG RELATED PROBLEMS IDENTIFIED THROUGH MEDICATION REVIEW IN ELDERLY PATIENTS IN PRIMARY HEALTHCARE

PS-079

IMPORTANCE OF HYPERCHOLESTEROLAEMIA IN PATIENTS WITH BIOLOGICAL TREATMENT FOR AUTOIMMUNE INFLAMMATORY DISEASE

Pages